



MS Connect

UPDATE REGARDING MOVECTRO

Tuesday 12 July 2011

Last month, Merck Serono announced that they were voluntarily withdrawing *Movectro*, an oral medication for multiple sclerosis (MS) from the Australian market.

The company advised that this occurred as a result of the decision not to pursue the global approval process for the medication.

While *Movectro* was registered with the Therapeutic Goods Administration (TGA) in September 2010, the company faced significant challenges in gaining registration through similar regulatory bodies in Europe and the United States of America. Approval in these countries would have required new clinical trial program, taking several years to complete, which the company chose not to pursue.

Merck Serono have since advised that all patients on the Patient Familiarisation Program will be permitted to continue the treatment until the conclusion of the treatment program.

Ends

People with MS should contact MS Connect on 1800 042 138 and their treating neurologist for any advice.

Media enquiries should be directed to Prue Guillaume on 0450 659 811.